MED2002 Licensing Deal

Futura Medical PLC
17 September 2007




For immediate release                                        17 September 2007


                               Futura Medical Plc
                          ('Futura' or 'the Company')

                     Signs global development and licensing
                              agreement for MED2002


Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative
products for the consumer healthcare market, is pleased to announce that it has
signed a global development, marketing and distribution agreement with SSL
International plc (LSE: SSL) for worldwide rights to MED2002, the Company's
topically applied gel for erectile dysfunction (ED).


Under the terms of the agreement with SSL, an undisclosed royalty on MED2002's
sales will be paid to Futura with milestone payments of up to £18 million,
subject to certain specified regulatory approvals and sales targets being
achieved. SSL and Futura will jointly manage the completion of the clinical
development programme of MED2002 currently expected to cost up to £3.65 million,
with SSL contributing 65 per cent of the costs and Futura contributing 35 per
cent.


Once launched, MED2002 is expected to become the world's first non-prescription
pharmaceutical treatment for men with ED, a condition that affects, to some
degree, 50 per cent of men aged 45 or over2. This would be an important step
forward as it is estimated that only 15 per cent of men with ED seek treatment3
due to the embarrassment of having to consult a doctor to be prescribed one of
the current treatments, all of which require a prescription.


This agreement with SSL further strengthens an existing relationship between
Futura and SSL which already holds the distribution rights for two of Futura's
products currently under development.


A development agreement for MED2002 was initially signed with GlaxoSmithKline
plc, which returned rights to the product to Futura as announced on 14 May 2007.


James Barder, Futura Medical's Chief Executive, said: 'We are delighted to have
signed such an important agreement with SSL and believe that the speed with
which SSL has entered this agreement is a significant endorsement of the
technical quality and commercial potential of MED2002.'


For any further information please contact:


Futura Medical plc
James Barder, Chief Executive                          Tel: [phone]
mail to: [e-mail]                www.futuramedical.co.uk


Canaccord Adams

Mark Ashurst

Tyler Broda                                            Tel: [phone]


For any media enquiries please contact:


Buchanan Communications
Mark Court / Rebecca Dietrich                          Tel: [phone]


Notes



Futura Medical plc


Futura Medical is a pharmaceutical group that develops innovative products for
consumer healthcare.  The Company is developing a portfolio of products and its
strategy is to license their manufacture and distribution to major
pharmaceutical and healthcare groups.


Futura is based in Guildford, Surrey, and its shares trade on the AIM market of
the London Stock Exchange.


www.futuramedical.co.uk


1. MED2002 is the term used by Futura to describe all the different gel
formulations applied directly to the penis for the treatment of male erectile
dysfunction. Futura may code certain formulations, for identification purposes,
by altering the final digit. For example MED2001 or MED2004.


2. Massachusetts Male Ageing Study (MMAS), J Urol 1994 Jan; ISI (1) : pages
54-61


3. Prog Urol February 2003, vol 13 part 1, pages 85-91


                      This information is provided by RNS
            The company news service from the London Stock Exchange